The next six months are dominated by the first full quarter under a brand-new CEO against a self-described "transition year" guide that already calls for revenue -2% to -5% and Adjusted EPS -4% to -13% in FY2026. Expectations have been reset low, buyback pace has been aggressive (roughly 13.9% of float retired in 2025), and management has explicitly told investors 2026 will not be the recovery year. The near-term calendar is therefore less about earnings beats and more about Dominic Brisby proving he can deliver against his own guide without a third consecutive year of negative organic volume.
No Results
The single datapoint that matters most is organic volume in Q1 FY26. Volume was negative in three of four quarters in 2025 and the Q1 2025 base was -3.6% — the easy comp. If Brisby cannot beat that, the "transition year" framing starts to feel like cover for structural decline. If he does, the ~21% trailing FCF yield begins to attract capital on the read that the category is stabilizing at a lower plateau rather than rolling over.
No analyst consensus or formal earnings calendar was in the dataset. The Q1 FY26 date reflects Nomad's historical May release cadence; the AGM slot follows the July 2025 pattern.
**Broken-LBO valuation is already priced in.** At $9.67 the stock trades at ~8.6x P/E, ~0.48x P/B, and a ~21% trailing FCF yield. Total cash-return yield is ~25%. Even if FCF contracts another 20% in FY26, the yield on current market cap stays in the mid-teens — the market is priced for a permanent step-down, not a transition year (Quant).
**Capital allocation has actually worked.** Share count fell from ~172M in 2021 to ~142M at year-end 2025 — an 18% float reduction at an average repurchase price well above current levels. Franklin's stake rose from 6.3% to 7.3% without buying a share, purely from float shrinkage. Continued buybacks at $9.67 compound per-share math faster than EBITDA needs to recover (Sherlock).
**The moat is real and the peer set is worse.** 15 country #1 positions in a category where freezer space is physically fixed. 12.8% ROIC versus Conagra 0.3% and Smucker negative; Campbell's fortress balance sheet is a different business. NOMD is smaller and more levered but generates more capital per dollar invested than the US packaged-food average (Warren).
**Expectations have been reset publicly.** The first full-year decline guide in company history, and the new CEO explicitly disavowed the prior regime's "growth-advantaged food company" language. The bar is now -2% to -5% revenue, not +3% — the cleanest setup for a beat since 2022 (Historian).
**Debt wall is pushed to 2032.** The November 2025 refi cost €75.9M one-time and extended maturities with the USD loan reset to $620M at SOFR+2.5%. Forced-refinancing tail risk is off the table for the next five years — the remaining question is coverage, not survival (Warren, Quant).
**Interest coverage halved in one year.** EBIT/interest went from 4.2x (FY24) to 2.2x (FY25) as interest expense jumped from $114M to $212M. Capital returns of $345M against $297M FCF equals 116% of FCF — the buyback that powers the per-share story is being financed, in part, by incremental debt. One more year of EBITDA compression forces the buyback to stop (Quant).
**Guidance credibility has collapsed.** Met-or-beat accuracy went 100% in 2023 → 67% in 2024 → 0% in 2025, with three in-year cuts each blamed on a different external cause (destocking, weather, UK softness, refi loss). The FY26 guide has no track-record cushion — it's being set by a CEO with zero quarters at the helm (Historian).
**Brisby has no frozen-food operating history.** Flora Food Group was plant-based spreads; Imperial Brands was tobacco. Zero Nomad shares at year-end 2025 and the promised open-market purchase has not yet been sized. In a category where the moat is defended SKU-by-SKU at retailer resets, category expertise is not optional — a transition year led by a learner is structurally slower (Sherlock).
**Related-party drag gets worse as the stock gets cheaper.** Mariposa + TOMS collect $4M/year in advisory fees to Franklin and Gottesman's family offices — effectively founder comp through the back door. At a $1.4B market cap that is ~0.3% of market cap a year for advice on acquisitions that have not happened since 2021. Chubb/APi insurance spend also scaled from €0.8M to €4.7M in a single year (Sherlock).
**Goodwill stack is vulnerable if the turnaround stalls.** €4.6B of goodwill and intangibles against €2.7B equity — tangible book is deeply negative. Two more years of negative organic volume in the Fortenova or Iglo cash-generating units and impairment becomes a live question. That would not affect cash flow, but it would visibly break the "cheap on book" leg of the thesis (Quant, Historian).
I'd lean cautious here, with a slight edge to the Against side. The tipping item is not valuation — which is genuinely cheap — but the guidance credibility collapse combined with the CEO unknown. The stock does not need a rerating to work; it needs one quarter of evidence that volume is stabilizing, and that evidence does not yet exist under Brisby. The bulls' best argument is the buyback flywheel, which has been per-share accretive and has real authorization left. The weakest is "the moat is real" — moats protect cash flows, not equity returns when interest coverage is 2.2x and 116% of FCF is already being paid out. I'd want one clean Brisby quarter — organic volume better than -2%, gross margin no worse than FY25, and buyback pace preserved without incremental debt — before adding. The condition that flips the view: a Q1 FY26 print with positive organic volume and evidence the €200M efficiency program is pulling forward into 2026 rather than loading to 2028. Short of that, the carry is real but the edge is thin.